Literature DB >> 33378304

Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer: Results From a Prospective Cohort Study.

Hee Jeong Kim1, Laura Dominici2,3, Shoshana M Rosenberg2, Yue Zheng2, Linda M Pak2,3, Philip D Poorvu2, Kathryn J Ruddy4, Rulla Tamimi3, Lidia Schapira5, Steven E Come6, Jeffrey Peppercorn7, Virginia F Borges8, Ellen Warner9, Hilde Vardeh10, Laura C Collins5, Rachel Gaither2, Tari A King2,3, Ann H Partridge2,3.   

Abstract

OBJECTIVE: We aimed to investigate eligibility for breast conserving surgery (BCS) pre- and post-neoadjuvant systemic therapy (NST), and trends in the surgical treatment of young breast cancer patients.
BACKGROUND: Young women with breast cancer are more likely to present with larger tumors and aggressive phenotypes, and may benefit from NST. Little is known about how response to NST influences surgical decisions in young women.
METHODS: The Young Women's Breast Cancer Study, a multicenter prospective cohort of women diagnosed with breast cancer at age ≤40, enrolled 1302 patients from 2006 to 2016. Disease characteristics, surgical recommendations, and reasons for choosing mastectomy among BCS-eligible patients were obtained through the medical record. Trends in use of NST, rate of clinical and pathologic complete response, and surgery were also assessed.
RESULTS: Of 1117 women with unilateral stage I-III breast cancer, 315 (28%) received NST. Pre-NST, 26% were BCS eligible, 17% were borderline eligible, and 55% were ineligible. After NST, BCS eligibility increased from 26% to 42% (P < 0.0001). Among BCS-eligible patients after NST (n = 133), 41% chose mastectomy with reasons being patient preference (53%), BRCA or TP53 mutation (35%), and family history (5%). From 2006 to 2016, the rates of NST (P = 0.0012), clinical complete response (P < 0.0001), and bilateral mastectomy (P < 0.0001) increased, but the rate of BCS did not increase (P = 0.34).
CONCLUSION: While the proportion of young women eligible for BCS increased after NST, many patients chose mastectomy, suggesting that surgical decisions are often driven by factors beyond extent of disease and treatment response.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33378304     DOI: 10.1097/SLA.0000000000004296

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  7 in total

1.  Smoking in bariatric surgery: a systematic review.

Authors:  Alexandra Chow; Amy Neville; Nicole Kolozsvari
Journal:  Surg Endosc       Date:  2020-06-10       Impact factor: 4.584

2.  Factors influencing the choice between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass.

Authors:  Hassan Nasser; Tommy Ivanics; Arthur M Carlin
Journal:  Surg Endosc       Date:  2020-09-09       Impact factor: 4.584

3.  Psychosocial and behavioral correlates of weight loss 12 to 15 years after bariatric surgery.

Authors:  Katy W Martin-Fernandez; David B Creel; Leslie M Schuh
Journal:  J Behav Med       Date:  2021-11-13

4.  Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Zhen-Yu Wu; Hee Jeong Kim; Jongwon Lee; Il Yong Chung; Jisun Kim; Sae Byul Lee; Byung-Ho Son; Eun Key Kim; Jae Ho Jeong; Hee Jin Lee; Eun Young Chae; Jinhong Jung; Sei-Hyun Ahn; BeomSeok Ko
Journal:  Breast Cancer Res Treat       Date:  2021-10-31       Impact factor: 4.872

5.  A knowledge gap unmasked: viral transmission in surgical smoke: a systematic review.

Authors:  Connal Robertson-More; Ted Wu
Journal:  Surg Endosc       Date:  2021-01-25       Impact factor: 4.584

6.  Taking a step down on the reconstruction ladder for head and neck reconstruction during the COVID-19 pandemic.

Authors:  Haroon Ur Rashid; Mamoon Rashid; Nasir Khan; Shayan Shahid Ansari; Noshi Bibi
Journal:  BMC Surg       Date:  2021-03-08       Impact factor: 2.102

Review 7.  Impact of smoking on weight loss outcomes after bariatric surgery: a literature review.

Authors:  Sukriti Mohan; Jamil S Samaan; Kamran Samakar
Journal:  Surg Endosc       Date:  2021-07-28       Impact factor: 4.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.